MARKET

SAGE

SAGE

Sage Therapeutic
NASDAQ
9.27
+0.06
+0.65%
After Hours: 9.23 -0.04 -0.43% 19:58 07/11 EDT
OPEN
9.19
PREV CLOSE
9.21
HIGH
9.36
LOW
9.13
VOLUME
3.06M
TURNOVER
--
52 WEEK HIGH
13.47
52 WEEK LOW
4.620
MARKET CAP
580.51M
P/E (TTM)
-1.5986
1D
5D
1M
3M
1Y
5Y
1D
Beyond The Numbers: 6 Analysts Discuss Sage Therapeutics Stock
Benzinga · 3d ago
Sage Therapeutics Price Target Cut to $9.20/Share From $12.00 by Scotiabank
Dow Jones · 3d ago
Sage Therapeutics Cut to Sector Perform From Sector Outperform by Scotiabank
Dow Jones · 3d ago
Scotiabank Downgrades Sage Therapeutics to Sector Perform, Lowers Price Target to $9.2
Benzinga · 3d ago
SAGE THERAPEUTICS INC <SAGE.O>: SCOTIABANK CUTS TO SECTOR PERFORM FROM SECTOR OUTPERFORM; CUTS TARGET PRICE TO $9.2 FROM $12
Reuters · 4d ago
Sage Therapeutics downgraded to Sector Perform from Outperform at Scotiabank
TipRanks · 4d ago
Weekly Report: what happened at SAGE last week (0630-0704)?
Weekly Report · 4d ago
Sage Therapeutics cutting over 330 jobs, Boston Globe reports
TipRanks · 07/01 13:30
More
About SAGE
Sage Therapeutics, Inc. is a biopharmaceutical company. The Company has developed two FDA-approved treatments indicated for postpartum depression (PPD) and is advancing a portfolio of internally discovered novel chemical entities with the potential to become differentiated treatments designed to improve brain health by primarily targeting two critical central nervous system, receptor systems, GABA and NMDA. Its product ZURZUVAE is for the treatment of PPD in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, and is the first oral, once-daily, 14-day treatment specifically indicated for adults with PPD. It is also evaluating potential indications for SAGE-324, a novel GABAA receptor positive allosteric modulator intended for chronic oral dosing, including seizures in developmental and epileptic encephalopathies. Its other areas of focus are SAGE-319, SAGE-039, and SAGE-817.

Webull offers SAGE Therapeutics Inc stock information, including NASDAQ: SAGE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SAGE stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SAGE stock methods without spending real money on the virtual paper trading platform.